Altshuler Shaham Ltd bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 136,348 shares of the company’s stock, valued at approximately $2,247,000. Other hedge funds have also modified […]
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) updated its FY 2023 earnings guidance on Thursday. The company provided EPS guidance of $3.16-$3.16 for the period. The company issued revenue guidance of $27.99 billion-$27.99 billion. Analysts Set New Price Targets Several equities analysts recently commented on the stock. TheStreet upgraded shares of Takeda Pharmaceutical from a […]
Legacy Financial Advisors Inc. increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 3.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,353 shares of the company’s stock after buying an additional 861 shares […]
Pacer Advisors Inc. increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 53.6% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,576,869 shares of the company’s stock after buying an additional 550,572 shares during the period. Pacer Advisors Inc.’s holdings in Takeda Pharmaceutical were worth $25,987,000 as of its […]
Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target […]